Evotec, Inserm, Lille University Hospital and Inserm Transfert Enter Collaboration to Identify Novel Therapeutic Targets in Obesity and Metabolic Diseases
Evotec, Inserm, Lille University Hospital and Inserm Transfert Enter Collaboration to Identify Novel Therapeutic Targets in Obesity and Metabolic Diseases
- Partnership will expand Evotec's molecular patient database in the area of metabolic diseases and in particular obesity
- Evotec will leverage its leading PanOmics technologies for the generation of large omics data sets including transcriptomics, proteomics and metabolomics
- Lille University Hospital will provide human biological samples and associated clinical data from its ABOS Biobank and will collect specific human biosamples for the collaboration
- All parties will jointly identify and validate novel key mechanisms of obesity & other metabolic diseases based on human data sets
- 此項合作將擴展Evotec的分子患者數據庫,在代謝疾病特別是肥胖症領域開展。
- Evotec將利用其領先的PanOmics技術生成大型組學數據集,包括轉錄組學、蛋白組學和代謝組學。
- 李爾大學醫院將提供其ABOS生物庫中的人體生物樣品和相關臨床數據,並收集特定的人體生物樣品用於合作。
- 所有參與方將聯合識別和驗證肥胖症和其他代謝疾病的新關鍵機制,基於人類數據集。
HAMBURG, GERMANY / ACCESSWIRE / May 30, 2024 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced that the Company entered a partnership with Inserm, the French National Institute of Health and Medical Research, Lille University Hospital and Inserm Transfert (the private subsidiary of Inserm) to identify novel therapeutic targets and diagnostic and prognostic markers in obesity and metabolic diseases.
德國漢堡/ACCESSWIRE/2024年5月30日/Evotec SE(法蘭克福證券交易所:EVT,MDAX/TecDAX,ISIN:DE0005664809;納斯達克:EVO)今天宣佈,該公司與法國國家衛生和醫學研究所(Inserm)、李爾大學醫院和Inserm轉化(Inserm的私有子公司)建立合作關係,以識別肥胖症和代謝疾病中的新治療靶點和診斷和預後標誌物。
Lille University Hospital is the sponsor of the clinical study entitled ABOS / DIABOMICS (Biological Atlas of Severe Obesity). In the framework of this study, started in 2012, Lille University Hospital develops and maintains the ABOS Biobank composed of a biobank and different associated databases dedicated to the study of obesity and its comorbidities.
李爾大學醫院是名爲ABOS / DIABOMICS(嚴重肥胖的生物圖譜)的臨床研究的贊助方。在這項於2012年開始的研究框架內,Lille大學醫院開發和維護了由生物庫和各種相關數據庫組成的ABOS生物庫,專門用於研究肥胖症及其併發症。
Obesity, a medical condition characterised by an excess accumulation of fat cells and uncontrolled ectopic fat deposition in the body, is currently recognised as one of the most important public health problems. It is estimated that over one billion adults globally will be affected by 2030. The strategic partnership between Evotec, Inserm, Lille University Hospital and Inserm Transfert aims at identifying novel multi-modality therapeutic targets. Evotec will gain access to a large patient cohort with severe obesity for the longitudinal assessment of metabolic outcomes after bariatric surgery-induced weight loss. The cohort consists of more than 8,000 human samples. Evotec will support the recruitment of 200 additional subjects within the next two years.
肥胖症是一種由於脂肪細胞過度積累和不受控制的體內異位脂肪沉積而特徵化的醫療狀況,目前被認爲是最重要的公共衛生問題之一。據估計,到2030年,全球有超過10億成年人受到影響。Evotec、Inserm、Lille大學醫院和Inserm轉化之間的戰略合作旨在找到新的多模式治療靶點。Evotec將獲得一個重度肥胖症患者隊列,以評估減重術誘導體重損失後代謝結局的長期評估。該隊列由超過8,000個人樣本組成。Evotec將在未來兩年內支持招募200名額外的被試者。
Under the agreement, Lille University Hospital will provide human biological samples and associated clinical data from its ABOS biobank and will collect specific human biological samples for the collaboration. Evotec will perform various omics studies on cohort samples to generate large omics data sets including transcriptomics, proteomics, and metabolomics data to better understand the etiology of metabolic diseases like metabolic dysfunction-associated steatohepatitis ("MASH"), obesity, diabetes, and cardiovascular disease. These PanOmics data will feed into Evotec's proprietary translational molecular patient data platform E.MPD, which serves as the central data repository for molecular patient data. The data will be analysed by all parties to identify and validate key mechanisms of obesity and other metabolic diseases.
根據協議,李爾大學醫院將提供其ABOS生物庫中的人體生物樣品和相關臨床數據,並收集特定人類生物樣品進行合作。Evotec將對群體樣本進行各種組學研究,生成包括轉錄組學、蛋白質組學和代謝組學數據在內的大型組學數據集,以更好地理解代謝疾病的病因,如代謝功能障礙相關脂肪肝(“MASH”)、肥胖症、糖尿病和心血管疾病等等。這些組學數據將被納入Evotec的專有轉化分子患者數據平台E.MPD,該平台作爲分子患者數據的中央數據倉庫。所有參與方將分析這些數據,以識別和驗證肥胖症和其他代謝疾病的關鍵機制。
Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: "We are excited to enter this partnership with Inserm and Lille University Hospital accessing a cohort of obese patients that is extremely well characterised. Currently over 40% of the US population suffers from obesity. The condition is a major health threat as it is connected to a plethora of other medical conditions such as type 2 diabetes, hypertension, cardiovascular disease, congestive heart failure, kidney disease and non-alcoholic fatty liver disease. This collaboration will help to understand obesity as a disease, something not achieved despite recent breakthroughs. Expanding our understanding of the key molecular mechanisms driving disease progression will allow us to identify and develop more effective but also safer treatment options than currently available."
Evotec首席科學官Cord Dohrmann博士評論道:“我們很高興與Inserm和Lille大學醫院建立這種合作關係,可以獲得極其充分的肥胖症患者隊列。目前,超過40%的美國人口患有肥胖症。由於與2型糖尿病、高血壓、心衰、腎臟疾病和非酒精性脂肪肝病等多種疾病存在關聯,因此肥胖症是一種重大的健康威脅。儘管取得了最近的突破,但仍未能理解肥胖症作爲一種疾病的本質。擴大對推動疾病進展的關鍵分子機制的理解,將使我們能夠確定並開發比當前可用的更有效,更安全的治療選擇。”
Prof. Francois Pattou, Translational Research Laboratory for Diabetes, Inserm UMR 1190 (under the joint supervision of Inserm, University of Lille and Lille University Hospital), PhD at Lille University Hospital, and Chairman of the Scientific Committee of Lille University Hospital ABOS Biobank, added: "Collaborating on cutting-edge science with a human data-centric approach gives us a unique opportunity to discover novel treatments for the benefit of patients living with obesity and metabolic diseases. The strong know-how and capabilities from Evotec will enable us to further strengthen and advance our research efforts within obesity and metabolic diseases based on human-relevant biology, to contribute to our overall mission of improving human health for all."
Lille大學和Lille大學醫院翻譯研究實驗室糖尿病轉化研究教授,Inserm UMR 1190(Inserm、Lille大學和Lille大學醫院聯合監督),Lille大學醫院ABOS生物庫科學委員會主席,博士Francois Pattou補充道:“與以人爲中心的數據爲基礎的尖端科學合作,爲我們提供了探索爲患有肥胖和代謝疾病的患者發現新治療方法的獨特機會。Evotec的強大專業知識和能力將使我們能夠進一步加強和發展基於以人類爲基礎的肥胖和代謝疾病的研究,以促進我們對改善所有人類健康的總體使命的貢獻。”
Prof. Bart Staels, Nuclear receptors, cardiovascular diseases and diabetes Laboratory, Inserm UMR 1011 (under the joint supervision of Inserm, Lille University Hospital, University of Lille and Institut Pasteur of Lille), said: "We are very excited about the collaboration and are confident that the combination of Evotec's excellent expertise and our commitment to therapeutic innovation, translational research, and multidisciplinary approaches, will open up new possibilities in discovery and development of novel drugs targeting obesity and metabolic diseases, with the potential to make a difference for patients living with these conditions."
Inserm UMR 1011(Inserm、Lille大學醫院、Lille大學和法國里爾巴斯德研究所聯合監督)核受體、心血管疾病和糖尿病實驗室的Bart Staels教授表示:“我們對此合作感到非常興奮,並相信Evotec的出色專業知識和我們對治療創新、轉化研究和多學科方法的承諾將爲發現和開發針對肥胖症和代謝疾病的新藥物打開新的可能性,對生活中患有這些疾病的患者產生積極影響。”
Noémie Pellegrin, Director of Industry Partnerships and Entrepreneurship of Inserm Transfert, adds: We are delighted with this research partnership, which capitalises on the wealth of know-how within the Inserm laboratories, the quality data from Lille University Hospital and the cutting-edge molecular translational technologies developed by Evotec. This collaboration will advance our understanding of obesity and associated metabolic diseases through the identification of key molecular mechanisms and new therapeutic targets.
Inserm Transfert的產業合作和創業負責人Noémie Pellegrin補充說:“我們對這個研究合作非常高興,它發揮了Inserm實驗室的豐富專業知識,來自Lille大學醫院的高質量數據和Evotec開發的前沿分子轉化技術。這種合作將通過在人類分子的背景下識別關鍵分子機制和新的治療靶點來推動我們對肥胖症和相關代謝疾病的理解。”
About Obesity
Obesity is defined as abnormal or excessive fat accumulation that presents a risk to health. A body mass index ("BMI") over 30 is obese. However, BMI categories for defining obesity vary by age and gender in infants, children, and adolescents. The issue has grown to epidemic proportions and obesity constitutes a major public health challenge that undermines social and economic development. The worldwide prevalence of obesity nearly tripled between 1975 and 2016. The World Obesity Federation estimates that by 2020 around 770 million adults globally were affected by obesity, and that figure is anticipated to exceed one billion by 2030. Once associated with high-income countries, obesity is now also prevalent in low-and middle-income countries, including among lower socio-economic groups. Overweight and obesity are caused by many factors including behaviours like eating patterns, lack of sleep or physical activity, and some medicines, as well as genetics and family history. Obesity is a chronic health condition that raises the risk for heart disease and is linked to many other health problems, including MASH, type 2 diabetes and cancer.
關於肥胖症
肥胖症被定義爲脂肪異常或過度積累,存在健康風險。BMI超過30即爲肥胖。然而,在嬰幼兒、兒童和青少年中,BMI類別的定義肥胖程度因年齡和性別而異。這個問題已經成爲流行病,肥胖構成了一個重大的關乎社會和經濟發展的公共衛生挑戰。肥胖的全球患病率在1975年至2016年間幾乎翻了三倍。據世界肥胖聯盟估計,2020年全球大約有7.7億成年人患有肥胖症,預計到2030年這一數字將超過10億。超重和肥胖的原因包括行爲(如飲食、缺乏睡眠或體育鍛煉),以及一些藥物,以及遺傳和家族史。肥胖是一種慢性健康狀況,它增加了患心臟病的風險,與許多其他健康問題有關,包括MASH、2型糖尿病和癌症等等。
About E.MPD
E.MPD, Evotec's translational molecular patient database, is one of the largest and highest quality molecular databases globally. Evotec's integrated technology platforms show that the best way to effectively treat disease is to identify underlying disease mechanisms and find the most suitable therapy on the basis of molecular data guiding all experimental processes towards early disease relevance. Therefore, data aggregation, integration, and the precise analysis of data is the critical path to effective and affordable medicine in the future.
關於E.MPD
E.MPD是Evotec的轉化分子患者數據庫之一,也是全球最大、最高質量的分子數據庫之一。Evotec的集成技術平台表明,有效治療疾病的最佳方法是確定潛在的疾病機制,並基於分子數據找到最適合的治療方案,引導所有實驗過程朝着早期疾病相關性的方向發展。因此,數據的彙總、集成和精確的分析是未來有效和經濟醫學的關鍵路徑。
E.MPD serves as the backbone for data-driven partnerships that will lead to innovative new medicines, better patient stratification, and potentially pave the way towards a new paradigm of more effective diagnostic and preventative healthcare. Through gathering and analysing patient-derived data in combination with AI/ML tools, Evotec is also able to better predict both safety and efficacy indicators in drug development.
E.MPD是以數據爲基礎的合作關係的支柱,這些關係將導致創新的新藥物、更好的患者分層,並有可能開闢一條通向更有效的診斷和預防保健的新範式之路。通過通過結合人類數據和AI/ML工具,收集並分析患者源數據,Evotec還能更好地預測藥物開發中的安全性和有效性指標。
About Inserm
Founded in 1964, Inserm is a public scientific and technological institute which operates under the joint authority of the French Ministries of Health and Research. The institute is dedicated to biomedical research and human health, and is involved in the entire range of activities from the laboratory to the patient's bedside. It also partners with the most prestigious research institutions in the world that are committed to scientific challenges and progress in these fields.
關於Inserm
Inserm成立於1964年,是一個公共的科學技術研究所,受法國衛生和研究部的聯合管理。該研究所致力於生物醫學研究和人類健康,涉及從實驗室到病牀的整個範圍的活動。它還與全球最着名的研究機構合作,致力於這些領域的科學挑戰和進展。
About Lille University Hospital
With over 16,000 professionals and 10 hospitals on a single campus, the Centre Hospitalier Universitaire de Lille is one of the four largest university hospital centers in France, and one of the largest in Northern Europe. As a regional referral centre as well as teaching, innovation and research hospital, it serves the 6 million inhabitants of the Hauts-de-France region. Lille University Hospital is strongly committed to the development of therapeutic innovation and clinical research. Its research strategy focuses on the early diagnosis and treatment of multi-factorial diseases, including cancer, neuroscience, cardiovascular, metabolic, inflammatory and infectious pathologies. For further information: , X/Twitter and LinkedIn.
關於Lille大學醫院
作爲地域板塊之一,里爾大學醫院集團擁有超過16000名專業人士和10家醫院。作爲地區轉診中心、教學、創新和研究醫院,里爾大學醫院集團爲上法蘭西大區的600萬居民提供醫療服務。里爾大學醫院集團致力於醫療創新和臨床研究的發展。其研究策略主要集中在多因素疾病的早期診斷和治療上,包括癌症、神經科疾病、心血管、代謝、炎症和感染病理學。若需了解更多信息,請參閱:, X/Twitter和頁面。LinkedIn.
About Inserm Transfert
Inserm Transfert, the private subsidiary of the French National Institute of Health and Medical Research (Inserm), is responsible for value creation of Inserm and its academic partners' innovations in human health and promotes long-term technology transfers in line with international best practices. Inserm Transfert SA was founded in 2000, and manages, under a Public Service Management Contract (Concession de Service Public) the entire innovation value chain and the transfer of knowledge from Inserm's research laboratories to industry, from invention disclosure to industrial partnerships and startups incorporation. Inserm Transfert also offers services relating to setting up and managing national, European and international projects, as well as supporting the technology transfer of clinical research and health data/databases and cohorts. For more information:
關於Inserm Transfert
Inserm Transfert是法國國家衛生和醫學研究所(Inserm)的私人子公司,負責增值Inserm及其學術合作伙伴創新的人類健康,並推廣符合國際最佳實踐的長期技術轉移。Inserm Transfert SA成立於2000年,根據公共服務管理合同(Concession de Service Public)管理整個創新價值鏈和知識轉移,從發明披露到工業夥伴關係和創業公司的成立。Inserm Transfert還提供有關建立和管理國家、歐洲和國際項目的服務,以及支持臨床研究和健康數據/數據庫和隊列的技術轉移。如需了解更多信息,請參閱:
About Evotec SE
Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Company's multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. Evotec provides high value pipeline co-creating partnerships and solutions to all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 200 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 5,000 highly qualified people. The Company's sites in Europe and the USA offer highly synergistic technologies and services and operate as complementary clusters of excellence. For additional information please go to and follow us on X/Twitter @Evotec and LinkedIn.
關於Evotec SE
Evotec是一家生命科學公司,擁有獨特的業務模式,實現其發現和開發高效治療方法並使患者受益的使命。公司的多模態平台包括一系列創新技術、數據和科學,用於發現、開發和生產一類和優秀的藥物產品。Evotec爲所有20大製藥公司和800多家生物技術公司、學術機構以及其他醫療保健利益相關者提供高價值的合作伙伴關係和解決方案。Evotec在一系列目前未得到充分服務的療法領域有戰略性活動,包括神經學、腫瘤學以及代謝和傳染性疾病。在這些專業領域內,Evotec旨在創建創新治療方法的世界領先的合作伙伴關係,並已經建立了一個由200多個獨有和合有的研發項目組成的組合,從早期發現到臨床開發。Evotec在全球擁有超過5000名高素質人才。該公司在歐洲和美國的網站提供高度協同的技術和服務,並作爲完善的卓越簇群運營。欲了解更多信息,請查看 並關注我們的X/Twitter @EvotecForward-looking-statements 和LinkedIn.
Forward-looking-statements
This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec's securities. Words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "should," "target," "would" and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec's expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.
本公告包含關於未來事件的前瞻性聲明,包括Evotec證券的招股說明。其包括對Evotec營收、集團EBITDA和未合作的研發費用的預期評論。這些前瞻性聲明基於Evotec在發表這些聲明時可獲得的信息和預期和假設,且Evotec認爲這屬於合理範圍內。不能保證這些預期將證明是正確的。這些聲明涉及已知和未知風險,並且基於一些假設和估計,這些假設和估計具有顯著不確定性和偶發事件,其中許多超出了Evotec的控制範圍。Evotec明確否認任何公開披露任何更新或修訂此類前瞻性聲明的義務或承諾,以反映此類聲明基於的任何期望或任何事件、狀況或環境的任何變化。
SOURCE: Evotec SE
For further information, please contact:
如需更多信息,請聯繫:
Media
媒體
Gabriele Hansen
SVP Head of Global Corporate Communications
Gabriele.Hansen@evotec.com
Gabriele Hansen
全球企業傳媒高級副總裁
Gabriele.Hansen@evotec.com
Hinnerk Rohwedder
Director of Global Corporate Communications
Hinnerk.Rohwedder@evotec.com
Hinnerk Rohwedder
全球企業傳媒董事
Hinnerk.Rohwedder@evotec.com
Investor Relations
投資者關係
Volker Braun
EVP Head of Global Investor Relations & ESG
Volker.Braun@evotec.com
Volker Braun
全球投資者關係與esg高級執行副總裁
Volker.Braun@evotec.com
SOURCE: Evotec SE
來源:Evotec SE